Patents Assigned to Intercept Pharmaceuticals, Inc.
  • TGR5 modulators and methods of use thereof
    Patent number: 9650409
    Abstract: The invention relates to compounds of Formula A: or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: May 16, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Farnesoid X receptor modulators
    Patent number: 9611289
    Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: April 4, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • TGR5 modulators and methods of use thereof
    Patent number: 9540414
    Abstract: The invention relates to compounds of Formula A: or a salt, solvate, or hydrate thereof. The compounds of formula A are TGR5 modulators useful for the treatment of disease.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: January 10, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Treatment of fibrosis using FXR ligands
    Patent number: 9498484
    Abstract: The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: November 22, 2016
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Stefano Fiorucci, Roberto Pellicciari, Mark Pruzanski
  • TGR5 modulators and methods of use thereof
    Patent number: 9243027
    Abstract: The invention relates to compounds of Formula A: or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including obesity, insulin sensitivity, inflammation, cholestasis, and bile desaturation.
    Type: Grant
    Filed: April 1, 2013
    Date of Patent: January 26, 2016
    Assignee: INTERCEPT PHARMACEUTICALS, INC.
    Inventor: Roberto Pellicciari
  • Preparation and uses of obeticholic acid
    Patent number: 9238673
    Abstract: The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: January 19, 2016
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: André Steiner, Heidi Waenerlund Poulsen, Emilie Jolibois, Melissa Rewolinski, Ralf Gross, Emma Sharp, Fiona Dubas-Fisher, Alex Eberlin
  • PROCESS FOR PREPARING BILE ACID DERIVATIVES
    Publication number: 20150291653
    Abstract: The present invention relates to processes for preparing compounds of formula I: or a pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: October 25, 2013
    Publication date: October 15, 2015
    Applicant: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Antimo Gioiello
  • Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
    Patent number: 9090652
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: July 28, 2015
    Assignee: INTERCEPT PHARMACEUTICALS, INC.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
  • TGR5 modulators and methods of use thereof
    Patent number: 8999964
    Abstract: The invention relates to compounds of Formula (A): (A) or a salt, solvate, hydrate, or amino acid conjugate thereof. The compounds of formula A are TGR5 modulators useful for the prevention and treatment of disease.
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: April 7, 2015
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Steroids as agonists for FXR
    Patent number: 8969330
    Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: March 3, 2015
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • TGR5 modulators and methods of use thereof
    Patent number: 8796249
    Abstract: The invention relates to compounds of Formula A: (A) or a salt, solvate, or hydrate thereof. The compounds of formula A are TGR5 modulators useful for the treatment of disease.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: August 5, 2014
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • TGR5 Modulators and Methods of Use Thereof
    Publication number: 20140100209
    Abstract: The invention relates to compounds of Formula A: or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.
    Type: Application
    Filed: April 26, 2013
    Publication date: April 10, 2014
    Applicant: INTERCEPT PHARMACEUTICALS, INC.
    Inventor: Intercept Pharmaceuticals, Inc.
  • TGR5 Modulators and Methods of Use Thereof
    Publication number: 20140094443
    Abstract: The invention relates to compounds of Formula A: or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including obesity, insulin sensitivity, inflammation, cholestasis, and bile desaturation.
    Type: Application
    Filed: April 1, 2013
    Publication date: April 3, 2014
    Applicant: INTERCEPT PHARMACEUTICALS, INC.
    Inventor: Intercept Pharmaceuticals, Inc.
  • Bile Acid Derivatives as FXR Ligands for the Prevention or Treatment of FXR-Mediated Diseases or Conditions
    Publication number: 20140057886
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Application
    Filed: August 28, 2013
    Publication date: February 27, 2014
    Applicant: INTERCEPT PHARMACEUTICALS, INC.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
  • Steroids as Agonists for FXR
    Publication number: 20140024631
    Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
    Type: Application
    Filed: February 7, 2013
    Publication date: January 23, 2014
    Applicant: INTERCEPT PHARMACEUTICALS, INC.
    Inventor: INTERCEPT PHARMACEUTICALS, INC.
  • Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
    Patent number: 8546365
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: October 1, 2013
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
  • TGR5 modulators and methods of use thereof
    Patent number: 8445472
    Abstract: The invention relates to compounds of Formula A: or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: May 21, 2013
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • 23-substituted bile acids as TGR5 modulators and methods of use thereof
    Patent number: 8410083
    Abstract: The invention relates to compounds of Formula A: (A) or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including obesity, insulin sensitivity, inflammation, cholestasis, and bile desaturation.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: April 2, 2013
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Steroids as agonists for FXR
    Patent number: 8377916
    Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: February 19, 2013
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Bile Acid Derivatives As FXR Ligands For The Prevention Or Treatment Of FXR-Mediated Diseases Or Conditions
    Publication number: 20120283234
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Application
    Filed: April 7, 2011
    Publication date: November 8, 2012
    Applicant: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski